Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice.
Caloric restriction (CR) mitigates neurological damage arising from aging and a variety of other sources, including neuropathology in young adult mice that express single and double transgenic (tg) mutations associated with Alzheimer disease (AD). To evaluate the potential of CR to protect against relatively heavy AD-type pathology, middle-aged (13-14-month-old) mice that co-express two mutations related to familial AD, amyloid precursor protein (APP) and presenilin 1 (PS1), were fed balanced diets with 40% fewer calories than ad libitum-fed controls. Following 18 weeks of treatment, mice were killed and brains were processed for quantification of total volume of amyloid-beta (Abeta) in the hippocampal formation and the overlying neocortex. Computerized stereology confirmed that CR reduced the total Abeta volume by about one-third compared to that in age-matched controls. Thus, CR appears to attenuate the accumulation of AD-type neuropathology in two cortical brain regions of middle-aged dtg APP/PS1 mice. These findings support the view that CR could be a potentially effective, non-pharmacology strategy for reducing relatively heavy Abeta deposition in older adult dtg APP/PS1 mice, and possibly afford similar protection against the onset and progression of AD in older adult humans.
Mouton
Peter R
PR
Laboratory of Experimental Gerontology, Gerontology Research Center, National Institute on Aging, Baltimore, MD 21224, United States. Moutonpe@mail.nih.gov
Chachich
Mark E
ME
Quigley
Christopher
C
Spangler
Edward
E
Ingram
Donald K
DK
D000375:Aging / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D031204:Caloric Restriction; D006624:Hippocampus / Q000378:metabolism*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D019579:Neocortex / Q000378:metabolism*
D016229:Amyloid beta-Peptides
Neuroscience. 2005;130(3):667-84
15590151
Neurobiol Aging. 2006 Nov;27(11):1694-704
16256248
BMJ. 2005 Aug 20;331(7514):455; author reply 455
16110085
Science. 2004 Sep 3;305(5689):1423-6
15353793
JAMA. 2000 Mar 22-29;283(12):1571-7
10735393
Ann N Y Acad Sci. 2000 Apr;903:335-44
10818523
J Neurosci. 2008 Dec 17;28(51):13805-14
19091971
Ann Neurol. 1990 May;27(5):457-64
2360787
Milbank Q. 1990;68(2):267-89
2233632
Neurobiol Dis. 2005 Apr;18(3):602-17
15755686
J Neurol Sci. 2004 Nov 15;226(1-2):31-3
15537515
J Neurochem. 2002 Feb;80(3):539-47
11905999
Neurobiol Aging. 1998 Sep-Oct;19(5):371-7
9880038
Arch Neurol. 2004 May;61(5):802-3; author reply 803
15148166
Neuron. 1996 Nov;17(5):1005-13
8938131
Behav Genet. 1999 May;29(3):177-85
10547924
Nutrition. 1989 May-Jun;5(3):155-71; discussion 172
2520283
J Comp Neurol. 2005 May 23;486(1):39-47
15834963
Arch Biochem Biophys. 1996 Sep 1;333(1):189-97
8806770
Neurobiol Dis. 1999 Aug;6(4):231-44
10448051
Neurobiol Dis. 2000 Aug;7(4):321-31
10964604
Am J Pathol. 2001 Mar;158(3):1173-7
11238065
J Chem Neuroanat. 2007 Nov;34(3-4):102-7
17658239
Science. 1992 Apr 10;256(5054):184-5
1566067
Gerontology. 1982;28(4):233-41
7117847
Neurobiol Aging. 2004 Mar;25(3):333-40
15123339
APMIS. 1988 May;96(5):379-94
3288247
Nat Med. 1998 Jan;4(1):97-100
9427614
FASEB J. 2005 Apr;19(6):659-61
15650008
Neuroreport. 2002 Mar 25;13(4):455-9
11930160
Nutr Rev. 2007 Sep;65(9):412-5
17958208
Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):686-92
18827571
Neuron. 1997 Oct;19(4):939-45
9354339
Exp Gerontol. 2000 May;35(3):299-305
10832051
J Nutr Biochem. 2005 Mar;16(3):129-37
15741046
Neurobiol Aging. 2008 Nov;29(11):1680-9
17524525
Ann N Y Acad Sci. 2004 Jun;1019:412-23
15247056
Neuroreport. 2005 Jul 13;16(10):1055-9
15973147
Exp Neurol. 2002 Feb;173(2):183-95
11822882
Nutr Neurosci. 2003 Jun;6(3):153-62
12793519
Neuroreport. 2004 Aug 6;15(11):1751-4
15257141
Neurobiol Aging. 2005 Jul;26(7):995-1000
15748777
Arch Pathol Lab Med. 1993 Feb;117(2):132-44
8427562
J Gerontol A Biol Sci Med Sci. 2004 May;59(5):405-7
15123747